Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a report published on Wednesday,Benzinga reports. HC Wainwright currently has a $15.00 target price on the stock.

A number of other analysts also recently commented on KPTI. Piper Sandler restated an “overweight” rating and set a $12.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Cantor Fitzgerald initiated coverage on Karyopharm Therapeutics in a research note on Thursday, February 5th. They set an “overweight” rating for the company. Royal Bank Of Canada cut their price objective on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday, November 4th. Wall Street Zen raised Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, The Goldman Sachs Group set a $12.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.83.

Karyopharm Therapeutics Price Performance

NASDAQ KPTI opened at $9.25 on Wednesday. The company has a market cap of $169.65 million, a P/E ratio of -0.56 and a beta of 0.21. Karyopharm Therapeutics has a 12 month low of $3.51 and a 12 month high of $10.38. The company has a 50-day moving average of $7.15 and a 200-day moving average of $6.35.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, February 12th. The company reported ($2.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.03. The company had revenue of $34.08 million during the quarter, compared to analyst estimates of $33.16 million. As a group, equities research analysts anticipate that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Trading of Karyopharm Therapeutics

Several large investors have recently bought and sold shares of the company. Baird Financial Group Inc. acquired a new position in shares of Karyopharm Therapeutics during the second quarter worth $45,000. State Street Corp grew its holdings in Karyopharm Therapeutics by 27.2% during the 4th quarter. State Street Corp now owns 58,942 shares of the company’s stock valued at $434,000 after purchasing an additional 12,600 shares in the last quarter. Tudor Investment Corp ET AL purchased a new stake in Karyopharm Therapeutics during the 4th quarter worth $95,000. XTX Topco Ltd acquired a new position in Karyopharm Therapeutics in the 2nd quarter worth $56,000. Finally, Persistent Asset Partners Ltd acquired a new position in Karyopharm Therapeutics in the 4th quarter worth $135,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.